The Effect of Ischaemic-Reperfusion and Remote Ischaemic Preconditioning in Man - A Bradykinin Dependent Pathway

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00965393

Enrollment

Registered

2009-08-25

Start date

2009-08-31

Completion date

2010-10-31

Last updated

2010-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischaemic Heart Diseases

Keywords

Ischaemia reperfusion, Platelet activation, Endothelial function, Remote ischaemic preconditioning, Bradykinin

Brief summary

Heart attacks are usually caused by a blood clot blocking an artery supplying blood to the heart. Current treatments are designed at relieving this blockage as quickly as possible to minimize damage to the heart muscle. However in restoring the supply of blood local damage known as ischaemia-reperfusion injury may occur. The aim of this study is to assess how clot forming and clot dissolving pathways are affected during this process, and examine the role of a natural inflammatory hormone, bradykinin. This will help the investigators to understand the mechanism by which ischaemia-reperfusion injury may occur and to devise new treatments for heart attacks.

Interventions

PROCEDUREForearm vascular study

Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.

DRUGPlacebo

Systemic infusion of placebo (saline)

DRUGbradykinin receptor antagonist (HOE-140)

Systemic infusion of bradykinin receptor antagonist (HOE-140)

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

MALE

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy males between 18-65 years of ages. * Non-smokers.

Exclusion criteria

* Any concurrent illness or chronic medical condition. * Concurrent use of vasoactive medication. * Smoking history.

Design outcomes

Primary

Measure	Time frame
Change in forearm blood flow in response to vasodilators (ACh(, ischaemia reperfusion and ischaemic preconditioning	20 fixed timepoints during each study visit (3hrs)

Secondary

Measure	Time frame
Change in platelet-monocyte-binding after ischaemia reperfusion and ischaemic preconditioning	4 fixed timepoints during each study visit (3hrs)

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026